Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
复制标题
DOI：
10.1093/annonc/mdi012
复制
发表时间：
2005-01-01
影响因子：
50.5
通讯作者：
Peace, J
中科院分区：
文献类型：
--
作者：
Crawford, SM;Peace, J
肿瘤标志物CA125是女性卵巢癌临床进展的重要指标。我们研究了从最低 CA125 值到进展的间隔：由 CA125 上升定义的离子（生化进展时间，TBP）。以及接受化疗治疗该疾病的患者的总体生存率与化疗后 CA125 最低值 < 30 U/ml 的患者的关系。 A组（38名患者，最低点小于或等于10 U/ml）的中位TBP为2436天，B组（32名患者，最低点11-20）为182天，C组（9名患者，最低点21-30）为90天（P < 0.001）。这与总生存期的相似差异相关，A 组的中位生存期为 2968 天，B 组为 537 天，C 组为 537 天（P < 0.001）。即使在正常范围内，CA125 值的变化也包含有用的信息。该预测指标将有助于研究一线化疗后患者的治疗管理。
The tumour marker CA125 is an important indicator of the clinical progress of women with carcinoma of the ovary. We have investigated the interval from the nadir CA125 value to progression:ion defined by rising CA125 (time to biochemical progression, TBP). and overall survival of patients treated with chemotherapy for this disease in relation to the nadir CA125 value in patients in whom this was < 30 U/ml following chemotherapy. The median TBP in group A (38 patients,nadir less than or equal to 10 U/ml) was 2436 days, in group B (32 patients, nadir 11-20) 182 days and in group C (nine patients. nadir 21-30) 90 days, (P < 0.001). This was associated with similar differences for overall survival, the median was 2968 days in group A, 537 days in group B and 537 days in group C, (P < 0.001). Variations in the CA125 value even within the normal range carry useful information. This propostic indicator will be useful in studying the management of patients following response to first-line chemotherapy.